Professor Jonathan Fallowfield
Jonathan Fallowfield's research interests span basic science and translational/clinical studies in hepatology. Key topics include mechanisms of liver fibrogenesis and fibrosis regression; portal hypertension and hepatorenal syndrome; biomarkers (particularly imaging); and discovery/development of novel therapies for liver fibrosis, NASH and portal hypertension. Engagement with industry is a high priority theme.
- Dr Fiona Gifford – Clinical Research Fellow (email)
Jonathan Fallowfield is a clinician scientist performing translational liver research, taking clinical problems across the scientific-clinical interface, identifying solutions and applying new ideas in patients. Engagement with Industry is a high priority theme.
I am Personal Chair of Translational Liver Research at the University of Edinburgh and Honorary Consultant Hepatologist at the Royal Infirmary of Edinburgh. During medical training in Southampton, I undertook an intercalated BSc focused on mechanisms of liver inflammation and a PhD investigating the reversibility of liver fibrosis as an MRC Clinical Research Training Fellow. I relocated to Edinburgh in 2008 as an Academy of Medical Sciences/Health Foundation Clinician Scientist Fellow determined to tackle the major unmet clinical need in hepatology for robust non-invasive biomarkers and effective treatments for patients with chronic liver disease. In 2014, I was awarded an NHS Research Scotland/Universities Senior Clinical Fellowship. My research interests span basic science and translational/clinical studies in hepatology. Key topics include mechanisms of liver fibrogenesis and fibrosis regression; portal hypertension and acute kidney injury; biomarkers (particularly imaging); and discovery/development of novel therapies for liver fibrosis, NASH and portal hypertension.
Track record in translation/commercialisation:
I have a successful track-record in translating scientific advances from bench-to-bedside and collaborating with Industry; demonstrating preclinical proof-of-concept for human-2 relaxin as an antifibrotic and vasoactive treatment in cirrhosis (Fallowfield et al, Hepatology 2014), then PI for a Novartis sponsored Phase II randomized trial of serelaxin in human cirrhosis (Snowdon et al, PLoS Med 2017), and currently PI for an investigator initiated Phase II trial of serelaxin in portal hypertension ('Serelaxin To Lower Portal Pressure in Patients With Cirrhosis and Portal Hypertension (STOPP)'; NCT02669875); awarded a GSK-DPAc in 2014 to discover a small-molecule agonist of the relaxin receptor (McBride et al, Sci Rep 2017); establishing macrophages as key players in the regression of liver fibrosis in rodents (Fallowfield et al, J Immunol 2007; Ramachandran et al, PNAS 2012), now co-I for Phase I/II cell therapy trial ('Autologous Macrophage Therapy for Liver Cirrhosis (MATCH)'; ISRCTN 10368050); co-PI for an Innovate UK grant to develop multiparametric MRI ('HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies'; NCT03213314); CI for a recently-funded Innovate UK precision medicine project (‘SteatoSITE: An Integrated Gene-To-Patient Data Commons for NAFLD Research'; lead preclinical drug development studies for novel liver disease therapeutics in collaboration with BioPharma partners.
Honours and Awards
- Intercalated BSc (1st Class) 1996
- Bachelor of Medicine (with Honours and Distinction in Clinical Medicine) 1997
- Membership of the Royal College of Physicians (London) 2000
- MRC Clinical Research Training Fellowship 2003-2006
- Academy of Medical Sciences/Health Foundation Clinician Scientist Fellowship 2008-2013
NRS/ Scottish Senior Clinical Fellowship 2014-
Membership of the Association of Physicians of Great Britain and Ireland
- Dr Anna Hoy (Postdoctoral scientist)
- Dr Joanne Morling (PhD student)
- Dr Victoria Snowdon (PhD student)
- Dr Neil Lachlan (Clinical Research Fellow)
- Li Xin (MSc student)
My clinical activity includes outpatient general hepatology (clinics, hepato-pancreato-biliary MDT). I also take an active role in teaching of preclinical and clinical trainees.
Sources of Funding
- Innovate UK
- Chief Scientist Office
- Medical Research Council
- Wellcome Trust
- The Academy of Medical Sciences
- The Health Foundation
- Scottish Funding Council
- Diabetes UK
- Edinburgh and Lothians Health Foundation